Priority HIV/AIDS Research within the Mission of NIDDK (R01 Clinical Trial Optional)
- Not stated
- Not stated
- Jan 8, 2025
Official announcement on the NIH Guide · opens the funder's page. Always confirm dates there.
Or read the full text and all 3 standing review criteria here, free with an account. Create free account
Summary
This Notice of Funding Opportunity (NOFO) seeks to stimulate HIV/AIDS research within the mission of the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) that aligns with the HIV/AIDS research priorities outlined by the NIH Office of AIDS Research (OAR)…
Related NIH announcements
NCCIH Natural Product Mid Phase Clinical Trial (R01 Clinical Trial Required)
Accelerating the Pace of Substance Use Research Using Existing Data (R01 Clinical Trial Not Allowed)
High Priority HIV and Substance Use Research (R01 Clinical Trial Optional)
INCLUDE Project: Transformative Research Awards for Down syndrome (R01 Clinical Trial Not Allowed)
$500k
Transformative Non-Invasive/Minimally Invasive Technologies for Imaging the Olfactory System Across Scales (R01 CT Optional)
$500k
The full announcement, free with an account
- The full announcement text, not just the first two sentences
- All 3 standing review criteria National Institutes of Health applies to this kind of proposal (its standard framework, not criteria written for this announcement)
On Plus, $39 a month
- The eligibility check against your profile: career stage, institution type, and the windows that close before the deadline does
- Funded precedents: what similar NIH projects received, from the award records in NIH RePORTER
- A Reviewer Scorecard of your draft against these criteria
More from National Institutes of Health
NIDCR Drug, Biologic, Device and/or Procedure Intervention Clinical Trial Planning and Implementation Cooperative Agreement (UG3/UH3 Clinical Trial Required)
Continuation of the Cardiovascular Repository for-Type 1 Diabetes (CARE-T1D) Consortium U01 (Open Competition)- Research (U01, Clinical Trial Not Allowed)
$500k